Podcast Summary
Zantac's Cancer-Causing Byproduct: Zantac contained a carcinogenic byproduct called NDMA, linked to cancer in animals and humans. The FDA recalled it in 2019, and long-term users should consult their healthcare provider or an attorney.
Zantac, a common over-the-counter medication for heartburn and reflux, contained a carcinogenic byproduct called NDMA when stored for extended periods. This byproduct, which forms when the renitidine molecule in Zantac reconnects, is a potent human carcinogen discovered in the 1930s and used in laboratory experiments to induce cancer in animals. Brent Wisner, a renowned attorney who has won numerous awards for his litigation skills, is currently handling cases related to Zantac and its health risks. The FDA recalled Zantac in 2019 due to the presence of NDMA, and it's essential for individuals who have taken Zantac for an extended period to be aware of the potential risks and consider speaking with their healthcare provider or consulting with an attorney.
Zantac's Impurity Linked to Various Types of Cancer: Zantac's active ingredient Ranitidine contains N-Nitrosodimethylamine (NDMA), a carcinogenic impurity linked to bladder, liver, stomach, colorectal, prostate, breast, pancreatic, and esophageal cancers. If diagnosed with one of these cancers, contact Obama Headland for potential litigation eligibility.
The drug Zantac, and specifically the active ingredient Ranitidine, contains a potentially carcinogenic impurity called N-Nitrosodimethylamine (NDMA). This impurity has been found in significant quantities in the drug itself, even before it is ingested. NDMA is known to interact with human DNA in a way that can cause miscodings, potentially leading to various types of cancer. Although NDMA can theoretically cause any type of cancer, the current focus of litigation is on cancers with substantial literature linking them to both MDMA and Ranitidine, such as bladder, liver, stomach, colorectal, prostate, breast, pancreatic, and esophageal cancers. If you or a loved one has been diagnosed with one of these cancers and believe that Zantac may have played a role, contact Obama Headland to discuss the possibility of joining the ongoing litigation. The process involves a thorough scientific evaluation to determine eligibility. While these cases can take years and involve thousands of people, Obama Headland has a proven track record of successfully representing clients in similar situations.
GSK Hid Cancer Risks of Zantac for Decades: GSK concealed high NDMA levels in Zantac for years, leading to potential cancer cases. Eligibility for litigation depends on length and frequency of use.
GlaxoSmithKline (GSK) sold Zantac, a heartburn medication, for decades while knowing it contained potentially carcinogenic levels of N-Nitrosodimethylamine (NDMA). The company conducted a study in 1982 that showed high levels of NDMA formation, but chose not to disclose the results to the Food and Drug Administration (FDA). Zantac was eventually pulled from the market in 2020 due to these findings. If you took Zantac and developed cancer, you may be eligible for litigation. The length of use and the amount taken regularly are important factors. The rule of thumb is taking it daily for at least a year, but sporadic use for a longer period could also qualify. Proof of use, such as receipts, is helpful but not always necessary. GSK invented the Zantac molecule and has been identified as the manufacturer responsible for this health crisis. The company's actions have led to a significant number of cancer cases. Lawsuits are being taken on in California and every other state.
Strategically filing cases in favorable jurisdictions: Law firms strategically file cases in jurisdictions with favorable jury pools and less conservative judicial systems to help clients navigate complex legal situations, such as the ongoing Zantac litigation against GSK, where evidence of harm far outweighs concerns about juries.
Law firms help clients navigate complex legal situations by strategically filing cases in jurisdictions with favorable jury pools and less conservative judicial systems. The ongoing Zantac litigation serves as an example, where the damning evidence against the manufacturer, GSK, and the potential harm caused to thousands of consumers, far outweighs concerns about juries. However, it's important to note that the evidence against Zantac, including early studies indicating its mutagenic properties, was ignored or downplayed by GSK and regulatory bodies. This case highlights the importance of transparency and accountability in the pharmaceutical industry, and the potential consequences when corporations prioritize profits over consumer safety.
Zantac Contained Potentially Carcinogenic Impurity: The FDA eventually pulled Zantac from the market after it was found to contain a potentially carcinogenic impurity, despite the drug being marketed for daily use and even with food, leading to increased risk. If you took Zantac and experienced health issues, consult with a qualified attorney for potential legal options.
The drug Zantac, also known as ranitidine, was found to contain a potentially carcinogenic impurity called N-Nitrosodimethylamine (NDMA). Despite this risk, the drug was marketed for daily use and even with food, which interacted with the drug and increased the risk. The Food and Drug Administration (FDA) eventually pulled Zantac from the market after manufacturers had already stopped selling it due to public pressure. The delay in the FDA's action was surprising, as regulatory agencies are often influenced by the industries they regulate. If you or someone you know took Zantac and developed health issues, it's important to consult with a qualified attorney to discuss potential legal options. Our firm, Baum Hedlund, based in Los Angeles, is currently handling Zantac lawsuits and can be reached at 855-948-5098 or through our website, baumhedlund.com. We are committed to helping our clients and getting to the bottom of their stories.
Zantac and Cancer: What You Need to Know: If diagnosed with cancer after taking Zantac, contact a lawyer for potential rights and compensation. Ongoing litigation against manufacturers could lead to compensation for affected individuals.
If you have taken Zantac and have been diagnosed with cancer, it's important to contact a lawyer to understand your potential rights. Brent Wisner, an experienced attorney, emphasized the significance of this matter and encouraged individuals to take action. He emphasized that the ongoing litigation against Zantac's manufacturer, Sanofi and Boehringer Ingelheim, could potentially lead to compensation for those affected. The discussion highlighted the potential link between Zantac and various types of cancer, and the ongoing investigation into the drug's safety. While the litigation process can be lengthy, it's crucial for those who may have been harmed to seek legal advice and explore their options. The discussion concluded with a reminder of the importance of staying informed and taking action if necessary.